Teva Partners with Fosun Pharma to Advance Novel Cancer Immunotherapy TEV-56278
The partnership will accelerate clinical data generation for TEV-56278, which is currently in a Phase 1 study for various forms of cancer, such as melanoma. TEV-56278 is an internally developed Teva product and is an anti-PD-1 antibody-cytokine fusion protein that uses Teva's proprietary ATTENUKINE technology.
A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company.
Its novel mechanism of action is designed to selectively deliver interleukin-2 (IL-2) to PD-1-expressing T cells within the tumor microenvironment. Under the terms of the agreement, Fosun Pharma has been granted an exclusive license to develop, manufacture, and commercialize TEV-56278 in mainland China, the Hong Kong SAR, Macau SAR, Taiwan region, and select Southeast Asian countries.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, manufactures, markets, and distributes generic & other medicines and biopharmaceutical products internationally. Fosun Pharma is a global healthcare company in pharmaceuticals, medical devices & diagnostics, and healthcare services.
While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the .
READ NEXT: and .
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Baxter International (BAX) Falls to New Low on Disappointing Growth Forecast
We recently published . Baxter International Inc. (NYSE:BAX) is one of the worst-performing stocks on Thursday. Baxter International dropped its share prices to a new 52-week low on Thursday, as investors soured on its lower earnings growth forecast. At intra-day trading, shares of Baxter International Inc. (NYSE:BAX) dropped to their lowest price of $21.47 before ending the day down by 22.42 percent at $21.76 apiece. In a call with analysts, Baxter International Inc. (NYSE:BAX) said it lowered its adjusted EPS to between $2.42 and $2.52 from the $2.47 to $2.55. Analysts expected $2.52 per share. 'While we never want to lower expectations, our overall objective is reducing the outlook to capture more of the potential downside risks,' Baxter International Inc. (NYSE:BAX) CFO Joel Grade was quoted as saying, underscoring the demand weakness for IV fluids. Pixabay / Public Domain In the second quarter of the year, Baxter International Inc. (NYSE:BAX) swung to a net income attributable to shareholders of $91 million from a $314 million net loss in the same period last year. Net sales inched up by 4 percent to $2.8 billion from $2.69 billion. While we acknowledge the potential of BAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
AB InBev (BUD) Sheds 13% as Investors Panic Over Declining Volumes
We recently published . Anheuser-Busch InBev SA/NV (NYSE:BUD) is one of the worst-performing stocks on Thursday. Anheuser-Busch dropped for a second day on Thursday, shedding 13.3 percent to close at $57.67 apiece as investor sentiment was dampened by declining volumes despite growing its earnings year-on-year. In its updated report, Anheuser-Busch InBev SA/NV (NYSE:BUD) said that beer and non-beer volumes declined by 1.9 percent in the second quarter of the year at 143,347 versus 146,302 in the same period last year amid weak industries and performance in China and Brazil. The first half of the year also saw total volumes dipping 2 percent to 279,615 from 285,837 in the same comparable period. Despite the volume drop, Anheuser-Busch InBev SA/NV (NYSE:BUD) still recorded a 13.8-percent jump in net income attributable to shareholders, to $1.676 billion from $1.472 billion in the same period last year, while revenues ended flat at $15 billion. Photo by Gio Bartlett on Unsplash In the first half, attributable net income increased by 49 percent to $3.8 billion from $2.56 billion year-on-year, while revenues decreased by 4.3 percent to $28.6 billion from $29.88 billion. While we acknowledge the potential of BUD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Arkham Says $3.5B LuBian Bitcoin Theft Went Undetected for Nearly Five Years
A crypto wallet tied to a little-known Chinese mining pool may have been the victim of the largest bitcoin theft ever recorded, according to new findings from Arkham Intelligence. In an Aug. 2 thread on X, the onchain analytics firm said it had uncovered evidence that 127,426 BTC — worth $3.5 billion at the time — was stolen from LuBian Mining Pool in late December 2020. Neither LuBian nor the suspected hacker has ever publicly acknowledged the breach, and Arkham said it is the first to report the incident. LuBian was one of the largest bitcoin mining pools globally in 2020, reportedly controlling nearly 6% of Bitcoin's total hash rate as of May that year. The hack, if confirmed, would eclipse the scale of other high-profile exploits like Mt. Gox and Bitfinex by nominal value at the time of loss. Arkham's analysis indicates that on Dec. 28, 2020, more than 90% of LuBian's BTC holdings were drained. Two days later, another theft involving about $6 million worth of BTC and USDT occurred, linked to a LuBian address operating on the Bitcoin Omni layer. The company appears to have moved its remaining 11,886 BTC — then worth hundreds of millions — into recovery wallets by Dec. 31, 2020. A notable detail in Arkham's report is the presence of OP_RETURN messages — special transactions that allow data to be embedded in the Bitcoin blockchain — sent from LuBian to the hacker. According to Arkham, the mining pool spent 1.4 BTC across over 1,500 transactions attempting to contact the thief, urging them to return the stolen funds. This effort suggests the messages were genuine and originated from the rightful wallet owner. Arkham believes the vulnerability may have stemmed from LuBian's use of a flawed private key generation algorithm that left it susceptible to brute-force attacks. The stolen BTC has apparently remained largely dormant, with the last major movement being a wallet consolidation in July 2024. Due to the price appreciation of bitcoin since 2020, the current value of the stolen assets is estimated to be $14.5 billion. That makes the wallet associated with the LuBian hacker the 13th largest BTC holder tracked by Arkham — surpassing the holdings linked to the Mt. Gox breach. As of today, both the hacker and LuBian are believed to still control their respective BTC balances. Arkham has published wallet trackers for both parties, but no additional details about the identities involved have been disclosed. Sign in to access your portfolio
